Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IOL Chemicals And PharmaceuticalsNSE:IOLCP -9.59%64 Earnings Yield (Joel Greenblatt) % is 9.65% as of Mar. 2026, which is 4% below its 10-year median of 10.04. GuruFocus rates NSE:IOLCP with a GF Score™ of 64/100 and a GF Value™ of ₹94.43 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,013 Drug Manufacturers companies, IOL Chemicals And Pharmaceuticals ranks better than 57.06% on this metric.
The historical rank and industry rank for IOL Chemicals And Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
NSE:IOLCP'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.58 Med: 10.04 Max: 58.56
Current: 4.63
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of IOL Chemicals And Pharmaceuticals was 58.56%. The lowest was 3.58%. And the median was 10.04%.
NSE:IOLCP's Earnings Yield (Joel Greenblatt) % is ranked better than 57.06% of 1013
companies
in the Drug Manufacturers industry
Industry Median: 3.29
vs NSE:IOLCP: 4.63
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. IOL Chemicals And Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was -10.85%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOL Chemicals And Pharmaceuticals Earnings Yield (Joel Greenblatt) % Chart
NSE:IOLCP vs ZTS, UTHR: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, IOL Chemicals And Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IOL Chemicals And Pharmaceuticals Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IOL Chemicals And Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where IOL Chemicals And Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
IOL Chemicals And Pharmaceuticals Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
IOL Chemicals And Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,989 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 9.65% mean?
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) has a Earnings Yield (Joel Greenblatt) % of 9.65% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on IOL Chemicals And Pharmaceuticals and its competitors. This is near median its historical median of 10.04. Over the past decade, IOL Chemicals And Pharmaceuticals' Earnings Yield (Joel Greenblatt) % has ranged from 3.58 to 58.56. According to the industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #435 out of 1013 companies in the Drug Manufacturers industry, placing it in the top 42.9%.
Is IOL Chemicals And Pharmaceuticals' Earnings Yield (Joel Greenblatt) % too high?
IOL Chemicals And Pharmaceuticals' current Earnings Yield (Joel Greenblatt) % of 9.65% is near median its 10-year median of 10.04. Over the past 10 years, this metric has ranged from a low of 3.58 to a high of 58.56. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.29. IOL Chemicals And Pharmaceuticals' value of 9.65% is 193.3% above this industry median. Based on the distribution chart, IOL Chemicals And Pharmaceuticals ranks #435 out of 1013 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, IOL Chemicals And Pharmaceuticals has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IOL Chemicals And Pharmaceuticals' Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #435 out of 1013 companies for Earnings Yield (Joel Greenblatt) %. This puts IOL Chemicals And Pharmaceuticals in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.29. IOL Chemicals And Pharmaceuticals' value of 9.65% is 193.3% above this benchmark. Historically, IOL Chemicals And Pharmaceuticals' own Earnings Yield (Joel Greenblatt) % has ranged from 3.58 to 58.56 over the past decade. While the company's 10-year median is 10.04 vs. the industry median of 3.29, IOL Chemicals And Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.29, based on 1,013 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IOL Chemicals And Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % of 9.65% is 193.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on IOL Chemicals And Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IOL Chemicals And Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % is 9.65%, which is near median its own 10-year median of 10.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IOL Chemicals And Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals (NSE:IOLCP) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹94.43, compared to a current price of ₹148.33 — trading 57.1% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 9.65%, which is near median its 10-year median of 10.04 and 193.3% above the Drug Manufacturers industry median of 3.29. IOL Chemicals And Pharmaceuticals' overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For IOL Chemicals And Pharmaceuticals (NSE:IOLCP), the current Earnings Yield (Joel Greenblatt) % is 9.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Overvalued in 2026?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹148.33 is trading 57.1% above its estimated GF Value™ of ₹94.43.
GuruFocus considers IOL Chemicals And Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:IOLCP:
Earnings Yield (Joel Greenblatt) %: 9.65% (near median its 10-year median of 10.04)
GF Value™: ₹94.43 vs. price of ₹148.33 (57.1% above fair value)
Industry Position: 193.3% above the Drug Manufacturers median (#435 of 1013)
No single metric tells the full story. See the NSE:IOLCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IOL Chemicals And Pharmaceuticals Business Description
IOL Chemicals And Pharmaceuticals Ltd is an India-based pharmaceutical company. The primary activity of the group is the manufacturing and sale of drugs and organic chemicals. The business activity is functioned through the Chemicals and Pharmaceutical segments. The Chemicals segment produces and sells chemicals such as Ethyl Acetate, Acetic Anhydride, Acetyl Chloride, Mono Chloro Acetic Acid, and Iso Butyl benzene, whereas the Pharmaceutical segment produces and sells various active pharmaceutical ingredients such as Ibuprofen, Metformin, Fenofibrate, Lamotrigine, and others. It derives prime revenue from the Pharmaceutical segment. Geographically, the group's products are sold in both the Indian and international markets.
64GF Score
Get the complete analysis for NSE:IOLCP
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IOLCP has been successfully added to your 
